| Date | Title | Description |
| 24.07.2025 | POP BIO and CEPI announce collaboration for faster responses to Disease X | POP BIO announces an award of up to $1.5M award from CEPI to advance the SNAP platform into the development of a SFTS vaccine BUFFALO, NY, UNITED STATES, July 24, 2025 /EINPresswire.com/ -- New research is set to investigate a pioneering a... |
| 26.11.2024 | POP BIO awarded $2.84M Phase II SBIR for seasonal influenza vaccine development | SNAP Platform
This grant will provide significant validation for the POP BIO SNAP technology to serve as a means of addressing the critical unmet need for a more effective vaccine against seasonal influenza.”
— Hilliard Kutscher, PhDBUFFALO... |
| 10.09.2024 | POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy | Concept for a polyvalent Alzheimer's Disease immunotherapy based on POP BIO's SNAP™ technology
POP BIO announces publication of “A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer’s diseas... |
| 21.08.2024 | POP BIO and FunPep Announce Collaboration for Antibody-Inducing Peptide Therapy | POP BIO and FunPep announce research collaboration
POP Biotechnologies announces the furtherance of research with FunPep. Advanced preclinical testing of antibody-inducing peptides will be carried out. BUFFALO, NY, 14228, August 21, 2024 /E... |
| 07.08.2024 | POP BIO and EuBiologics’ Shingles Vaccine Enters Phase 1 Clinical Trials | POP Biotechnologies
SNAP Platform
POP Biotechnologies announces the commencement of dosing of the shingles vaccine “EuHZV” in collaboration with EuBiologics in a Phase 1 clinical study in Korea
The commencement of this new clinical trial fu... |
| 30.11.2022 | POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19 | EuCorVac-19, a novel COVID-19 vaccine currently in Phase 3 clinical trials.
POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2 clinical trial of EuCorVac-19. BUFFALO, ... |
| 21.09.2022 | POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19 | EuCorVac-19, a novel COVID-19 vaccine currently in Phase 3 clinical trials.
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19 with Eubiologic's EuCorVac-19
This milestone provides validatio... |
| 07.02.2022 | POP Biotechnologies' next-gen vaccine technology to enter COVID-19 phase III clinical trials | POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ... |
